242 related articles for article (PubMed ID: 19826974)
41. Predicting idiosyncratic drug-induced liver injury: some recent advances.
Chen M; Borlak J; Tong W
Expert Rev Gastroenterol Hepatol; 2014 Sep; 8(7):721-3. PubMed ID: 24857265
[TBL] [Abstract][Full Text] [Related]
42. Mechanisms of isoniazid-induced idiosyncratic liver injury: emerging role of mitochondrial stress.
Boelsterli UA; Lee KK
J Gastroenterol Hepatol; 2014 Apr; 29(4):678-87. PubMed ID: 24783247
[TBL] [Abstract][Full Text] [Related]
43. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis.
Cho HJ; Koh WJ; Ryu YJ; Ki CS; Nam MH; Kim JW; Lee SY
Tuberculosis (Edinb); 2007 Nov; 87(6):551-6. PubMed ID: 17950035
[TBL] [Abstract][Full Text] [Related]
44. Flucloxacillin-induced liver injury.
Andrews E; Daly AK
Toxicology; 2008 Dec; 254(3):158-63. PubMed ID: 18793693
[TBL] [Abstract][Full Text] [Related]
45. Genome-Wide Association Studies in Drug-Induced Liver Injury: Step Change in Understanding the Pathogenesis.
Aithal GP; Grove JI
Semin Liver Dis; 2015 Nov; 35(4):421-31. PubMed ID: 26676816
[TBL] [Abstract][Full Text] [Related]
46. Are Polymorphisms in Genes Relevant to Drug Disposition Predictors of Susceptibility to Drug-Induced Liver Injury?
Daly AK
Pharm Res; 2017 Aug; 34(8):1564-1569. PubMed ID: 28028769
[TBL] [Abstract][Full Text] [Related]
47. Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis.
Kim SH; Kim SH; Bahn JW; Kim YK; Chang YS; Shin ES; Kim YS; Park JS; Kim BH; Jang IJ; Song J; Kim SH; Park HS; Min KU; Jee YK
Pharmacogenomics; 2009 Nov; 10(11):1767-79. PubMed ID: 19891553
[TBL] [Abstract][Full Text] [Related]
48. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period.
Andrade RJ; Lucena MI; Fernández MC; Pelaez G; Pachkoria K; García-Ruiz E; García-Muñoz B; González-Grande R; Pizarro A; Durán JA; Jiménez M; Rodrigo L; Romero-Gomez M; Navarro JM; Planas R; Costa J; Borras A; Soler A; Salmerón J; Martin-Vivaldi R;
Gastroenterology; 2005 Aug; 129(2):512-21. PubMed ID: 16083708
[TBL] [Abstract][Full Text] [Related]
49. Drug-induced liver injury due to antimicrobials, central nervous system agents, and nonsteroidal anti-inflammatory drugs.
Devarbhavi H; Andrade RJ
Semin Liver Dis; 2014 May; 34(2):145-61. PubMed ID: 24879980
[TBL] [Abstract][Full Text] [Related]
50. Drug associated hepatic reactions in New Zealand: 21 years experience.
Pillans PI
N Z Med J; 1996 Aug; 109(1028):315-9. PubMed ID: 8816722
[TBL] [Abstract][Full Text] [Related]
51. Antituberculosis drug-induced hypersensitivity syndrome and its association with human leukocyte antigen.
Kim SH; Lee SK; Kim SH; Park HW; Chang YS; Lee KW; Jee YK
Tuberculosis (Edinb); 2013 Mar; 93(2):270-4. PubMed ID: 23153709
[TBL] [Abstract][Full Text] [Related]
52. Pharmacogenetics of drug-induced liver injury.
Russmann S; Jetter A; Kullak-Ublick GA
Hepatology; 2010 Aug; 52(2):748-61. PubMed ID: 20607838
[TBL] [Abstract][Full Text] [Related]
53. An update of adverse drug reactions of relevance to general dental practice.
Flint SR; O'Sullivan C; Arthur N
J Ir Dent Assoc; 2000; 46(2):67-70. PubMed ID: 11326529
[No Abstract] [Full Text] [Related]
54. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis.
Huang YS; Chern HD; Su WJ; Wu JC; Chang SC; Chiang CH; Chang FY; Lee SD
Hepatology; 2003 Apr; 37(4):924-30. PubMed ID: 12668988
[TBL] [Abstract][Full Text] [Related]
55. Flucloxacillin-Induced Hepatotoxicity - Association with HLA-B*5701.
Teixeira M; Macedo S; Batista T; Martins S; Correia A; Matos LC
Rev Assoc Med Bras (1992); 2020; 66(1):12-17. PubMed ID: 32130375
[TBL] [Abstract][Full Text] [Related]
56. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury.
Huang YS; Su WJ; Huang YH; Chen CY; Chang FY; Lin HC; Lee SD
J Hepatol; 2007 Jul; 47(1):128-34. PubMed ID: 17400324
[TBL] [Abstract][Full Text] [Related]
57. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis.
Lee SW; Chung LS; Huang HH; Chuang TY; Liou YH; Wu LS
Int J Tuberc Lung Dis; 2010 May; 14(5):622-6. PubMed ID: 20392357
[TBL] [Abstract][Full Text] [Related]
58. Epidemiology and Genetic Risk Factors of Drug Hepatotoxicity.
Ahmad J; Odin JA
Clin Liver Dis; 2017 Feb; 21(1):55-72. PubMed ID: 27842775
[TBL] [Abstract][Full Text] [Related]
59. Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury.
Kim SH; Saide K; Farrell J; Faulkner L; Tailor A; Ogese M; Daly AK; Pirmohamed M; Park BK; Naisbitt DJ
Hepatology; 2015 Sep; 62(3):887-99. PubMed ID: 25998949
[TBL] [Abstract][Full Text] [Related]
60. Contribution of HLA genes to genetic predisposition in diffuse panbronchiolitis.
Keicho N; Tokunaga K; Nakata K; Taguchi Y; Azuma A; Bannai M; Emi M; Ohishi N; Yazaki Y; Kudoh S
Am J Respir Crit Care Med; 1998 Sep; 158(3):846-50. PubMed ID: 9731015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
